The Global Needle-free Delivery Technology Market Will Reach $2.4 Billion in 2017 Predicts New Visiongain Report

LONDON, May 7, 2013 /PRNewswire/ --

A new report by visiongain predicts that the global market for needle-free delivery technology will reach $2.4bn in 2017. That revenue forecast and others appear in Needle-Free Delivery: Technology and Market 2013-2023, published in April 2013. Visiongain is a business information provider based in London, UK.

Needle-free delivery devices will have significant opportunities for growth. Visiongain believes market expansion will be driven by new technologies, reduced prices and increasing efficiency in manufacturing processes. Needle-free delivery technology encompasses all delivery technologies which are minimally invasive including jet injectors, microneedles, pen needles, inhalers and patches. Jet injectors are a well established, expanding segment of the market. In addition, innovative technologies such as microneedle patches will drive growth.

Amritha.M.Ramakrishnan, healthcare industry analyst in visiongain says "The push to develop needle-free technology has largely arisen due to strong demand from patient groups seeking alternatives to traditional needle-based systems. Needle stick injury and needle phobia are the primary factors helping to drive many markets towards the use of needle-free delivery technology. Market growth is also linked to an increase in prevalence of diseases worldwide.

 "The overall needle-free technology market is achieving explosive growth and this trend will continue during the forecast period. Needle-free technology offers advantages over conventional technologies including enhanced safety, increased immunogenicity in vaccinations and fewer injection site lesions. Needle-free technology will be increasingly used for mass immunisations and delivery of biologics. However, this will depend upon more clinical evidence becoming available, making the technology more attractive to pharmaceutical companies. The high cost of needle-free technology is another issue currently restraining growth. Despite all of these challenges, experts in the field are optimistic about the opportunities lying ahead for the needle-free market."

Visiongain believe that the overall needle-free technology market will benefit from its extensive development pipeline, with a number of products expected to be launched over the next 10 years. The US is currently the leading national market, while emerging countries like China and India are predicted to play a significant role in the second half of the forecast period.

Visiongain's report shows revenue forecasts to 2023 at overall world market, submarket and national level. It forecasts world sales for the following submarkets:

• Jet injectors market
• Competing needle-free technology market

This study also includes forecasts for the following subsectors:

• Novel needle technology (includes microneedles and pen needles)
• Inhaler technology
• Patch technology.

Research, data and analyses cover activities of leading companies, including Antares Pharma, Zogenix, Bioject Medical Technologies and 3M.

The study includes researching trends and forecasting revenues in leading national markets. Countries analysed are the US, Japan, Germany, France, the UK, Spain, Italy, India and China. The analysis also discusses opportunities and developments - technological and commercial.

Needle-Free Delivery: Technology and Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report The global needle-free delivery technology market   please visit

http://www.visiongain.com/Report/1030/Needle-Free-Delivery-Technology-And-Market-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Companies Listed

3M
Actavis
Activa Brand Products
Acushot
Alkermes
Altea Development Corporation
Alza
Anesiva
Antares Pharma
Astellas Pharma
Astra Zeneca
Australian Institute for Bioengineering and Nanotechnology
Becton Dickinson
Berlex Labs
Bespak
Bioject Medical Technologies
Boehringer Ingelheim
Cambridge Consultants
Center for Devices and Radiological Health (CDRH)
Corium International
Crossject Medical Technologies
CSL Behring
CSL Biotherapies
D'Antonio Consultants International
Daewoong Pharmaceuticals
Debiotech
Diabetes Management International
Durect
Echo Therapeutics
Elan Corporation
Eli Lily &Co
Eloquest Healthcare
EMD Serono
Emory University
Eurojet Medical
Ferndale Pharma Group
Ferring Pharmaceuticals
Food and Drug Administration (FDA) US
Generex
Georgia Tech's School of Chemical and Biomolecular Engineering
GlaxoSmithKline (GSK)
Glide Pharmaceutical Technologies
Gwangju Institute of Science and Technology
Harvard University
Indian Institute of Science, Bangalore
Intercell
Janssen Pharmaceuticals
JCR Pharmaceuticals
John Hopkins Bloomberg School of Public Health
Key Pharmaceuticals
Lederle Labs
Leiden University
LigoCyte Pharmaceuticals
Mannkind
Medical International Technologies
MedImmune
Merck &Co
NanoBiosciences
Nanopass Technologies
National Health Service (NHS)
National Institute of Health (NIH)
National Medical Products
Nektar Therapeutics
Nemaura Pharma
Novartis
Novo Nordisk
NuPathe
Nycomed
Ortho-McNiel
Owen Mumford
Parke-Davis
PenJet Corporation
Pfizer
Pharmacia and Upjohn Company
Pharmajet
PKA SoftTouch Corp
PowderJect Pharmaceuticals
Procter and Gamble
Sanofi
Sanofi-Pasteur
Schering
Schwarz Pharma
Serum Institute of India
Shreya Life Sciences
Stat Medical Devices
State Food and Drug Administration (SFDA) China
Teva Pharmaceuticals
TheraJect
Theratechnologies
Trinity Chiesi
UCB
University Erlangen-Nurnberg
University of California
University of Colorado
University of Queensland
Watson Pharmaceuticals
World Health Organization (WHO)
Zogenix
Zosano Pharma
Zydus Cadila

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Automotive and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100